PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models
Led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Experimental Therapeutics Group, in collaboration with VHIO's Hereditary Cancer Genetics Group and the Medical Oncology Department at the Vall d'Hebron ...
Sep 3, 2024
0
1